 |
Jaehyung Yoon
|
09/02/09 at 8:42 AM CDT |
News |
Genzyme Corporation Announces FDA Advisory
Committee Recommends Randomized Trial To Support Proposed
Indication For Clolar In Adult AML Tuesday...
|
62
|
-
|
-
|
-
|
-
|
|
Jaehyung Yoon
|
08/10/09 at 2:00 PM CDT |
News |
I don't know enough to compare/contrast
Genzyme and Shire in depth, but here are the major differences on
the surface: Genzyme is a biotechnol...
|
50
|
-
|
-
|
-
|
1
|
 |
Perry Rod
100% / 1 Member
|
08/07/09 at 12:40 PM CDT |
News |
Thanks for that. Are Shire and GENZ pretty
similar companies overall? GENZ trades at a wayy better value
and with a much cleaner balance ...
|
42
|
1
|
-
|
-
|
-
|
|
Jaehyung Yoon
|
08/07/09 at 8:45 AM CDT |
News |
Genzyme's blockbuster product in the
genetic disorder is Cerezyme for Gaucher diseases. Comparable
to the blockbuster are Shire's velaglu...
|
54
|
1
|
-
|
-
|
2
|
|
Perry Rod
100% / 1 Member
|
08/06/09 at 11:51 PM CDT |
News |
Wow GENZ has really been left out of the
recent rally ..seems like a smart idea. Analysts are actually
not that sour on it..lowest sell s...
|
38
|
1
|
-
|
-
|
-
|
|
Jaehyung Yoon
|
08/06/09 at 3:39 PM CDT |
News |
European Commission Approves Genzyme's
Mozobil Genzyme Corporation (Nasdaq: GENZ) announced today that the
European Commission has granted mark...
|
56
|
1
|
-
|
-
|
-
|
